Two pivotal studies of LITFULO™ (ritlecitinib) in nonsegmental vitiligo met their co-primary endpoints, showing significant improvement in facial and total repigmentation versus placebo at Week 52 ...
Data indicate that the 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, induces a strong immune response against contemporary circulating and emerging lineages ...
/Pfizer%20Inc_%20NY%20HQ-by%20JHVEPhoto%20via%20iStock.jpg)
While Pfizer has trailed the broader market over the past year, Wall Street still sees room for upside and remains moderately optimistic about the company's prospects.
Supplemental application aims to expand use to men with HRR gene-mutated metastatic castration-sensitive prostate cancer Filing supported by Phase 3 TALAPRO-3...
1 Stock Under $50 to Target This Week and 2 We Question
/Pfizer%20Inc_%20logo%20sign-by%20JHVEPhoto%20via%20iStock.jpg)
Pfizer is set to announce its second-quarter earnings next month, and Wall Street expects a double-digit decline in its profit.
Wainua missed its Phase 3 endpoint, hitting Ionis Pharmaceuticals hard while AstraZeneca absorbed the blow easily, boosting rivals BridgeBio, Pfizer and Alnylam Pharmaceuticals.
2 Value Stocks Worth Your Attention and 1 Facing Headwinds
First and only treatment regimen for adults with MIBC, regardless of cisplatin eligibility, representing a platinum-free potential standard of care Broadened...
1 Healthcare Stock with Solid Fundamentals and 2 We Brush Off